

01-13-04

Response Under 37 CFR §1.116  
Expedited Procedure  
Examining Group 1617

1 AF  
\$1817



CASE 4-30755B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 335542795US  
Express Mail Label Number

January 12, 2004  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
BULLOCK ET AL.  
APPLICATION NO: 10/072,516  
FILED: FEBRUARY 6, 2002  
FOR: ADDITIONAL THERAPEUTIC USE

Art Unit: 1617  
Examiner: Kim, J.

RECEIVED  
JAN 22 2004  
TECH CENTER 1600/2900

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL REJECTION

Sir:

In response to the Office Action mailed July 11, 2003, applicants in the above-identified patent application respectfully request the following amendment be entered and the claims considered in light thereof. Applicants also herein request a three month extension for this response as allowed under 37 C.F.R. § 1.136(a). The Examiner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis Corporation for the fee required under 37 C.F.R. § 1.17(a).

IN THE CLAIMS:

Claim 7 has been deleted and claims 8, 9, 11, and 12 have been amended as shown in the attached amendment sheet which follows the REMARKS Section of this response.

REMARKS:

The Applicants have deleted claim 7 and amended claims 8, 9, 11, and 12 to clarify the novelty and unobvious nature of the Applicants' invention.